Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.57 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.57 |
| ▸ | SHBG | P04278 | 3/20 | 0.57 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.57 |
| ▸ | PGR | P06401 | 1/20 | 0.57 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.57 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | AR | P10275 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | MGAM | O43451 | 1/20 | 0.57 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4255342 | 1.00 | MEN1 (0.67) | MEN1KMT2ACYP19A1GPBAR1SHBG | |
| SCHEMBL6130933 | 0.87 | MEN1 (0.58) | MEN1KMT2ACYP19A1GPBAR1SHBG | |
| SCHEMBL14121739 | 0.86 | ABCB1 (0.54) | MEN1KMT2ACYP19A1GPBAR1SHBG | |
| SCHEMBL14121738 | 0.86 | ABCB1 (0.54) | MEN1KMT2ACYP19A1GPBAR1SHBG | |
| SCHEMBL6130951 | 0.86 | MEN1 (0.55) | MEN1KMT2ACYP19A1GPBAR1SHBG | |
| SCHEMBL6913689 | 0.85 | MEN1 (0.72) | MEN1KMT2ACYP19A1GPBAR1SHBG | |
| SCHEMBL23363784 | 0.84 | MEN1 (0.73) | MEN1KMT2ACYP19A1GPBAR1SHBG | |
| SCHEMBL10971884 | 0.84 | MEN1 (0.73) | MEN1KMT2ACYP19A1GPBAR1SHBG | |
| SCHEMBL4252612 | 0.84 | MEN1 (0.73) | MEN1KMT2ACYP19A1GPBAR1SHBG | |
| SCHEMBL6942662 | 0.84 | MEN1 (0.73) | MEN1KMT2ACYP19A1GPBAR1SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4726059-A1 | CORRELATION OF AKR1C3 ENZYME EXPRESSION LEVEL WITH KRAS MUTATION, AND MEDICAL USE | Ascentawits Pharmaceuticals, Ltd. (CN) | 2026-04-15 | — | — | EP | disclosed |
| US-20260014080-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | VAN BOGAERT GINA (BE) | 2026-01-15 | — | — | US | disclosed |
| US-20250281509-A1 | SEQUENTIAL HORMONE THERAPY TO IMPROVE SURVIVAL AND ENHANCE RESPONSE TO IMMUNE THERAPY IN MEN WITH PROSTATE CANCER | THE JOHNS HOPKINS UNIVERSTY | 2025-09-11 | — | — | US | disclosed |
| US-20250137012-A1 | COMPOSITIONS AND METHODS OF USING TWO-PROMOTER VECTOR FOR TREATMENT OF LYSOSOMAL STORAGE DISORDERS | M6P THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| CN-119630691-A | Method for treating muscular dystrophy | 萨勒普塔医疗公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2024251193-A1 | CORRELATION OF AKR1C3 ENZYME EXPRESSION LEVEL WITH KRAS MUTATION, AND MEDICAL USE | 深圳艾欣达伟医药科技有限公司 | 2024-12-12 | — | — | WO | disclosed |
| EP-4472657-A1 | COMPOSITIONS AND METHODS OF USING TWO-PROMOTER VECTOR FOR TREATMENT OF LYSOSOMAL STORAGE DISORDERS | M6P Therapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-111741979-B | Her 2-targeted antigen binding molecules comprising 4-1BBL | 豪夫迈·罗氏有限公司 | 2024-07-02 | — | — | CN | disclosed |
| WO-2023223235-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | PURNA PHARMACEUTICALS NV (BE) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023150051-A1 | COMPOSITIONS AND METHODS OF USING TWO-PROMOTER VECTOR FOR TREATMENT OF LYSOSOMAL STORAGE DISORDERS | M6P THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| CN-109971720-B | Chimeric antigen receptor modified T cells targeting ErbB receptor family and uses thereof | 上海细胞治疗研究院 | 2023-06-20 | — | — | CN | disclosed |
| WO-2023028084-A2 | METHODS AND COMPOSITIONS OF NUCLEIC ACID ENCAPSULATED WITHIN EXTERNAL MEMBRANES | Coastar Therapeutics Inc. (US) | 2023-03-02 | — | — | WO | disclosed |
| CN-107840888-B | Mediterranean and mesomeric binding antibodies and uses thereof | 希望之城公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | MEN1 3638/4885KMT2A 1108/4885CYP19A1 1933/4885 |
| US-20260014080-A1 | LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF | NR5A1, SHBG, GNRHR | MEN1 748/4885KMT2A 3205/4885CYP19A1 13/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | MEN1 4701/4885KMT2A 2353/4885CYP19A1 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.